University of Glamorgan

Cardiff • Pontypridd • Caerdydd

Genomics Policy Insight informing the new era of genomic-based medicine, from the Genomics Policy Research Unit

Members of the Genetics and Merthyr Youth – GAMY project and the Genomics Policy Unit (GPU) attended the Beacon for Wales showcase event in the Senedd in Cardiff Bay yesterday afternoon.

The Beacon for Wales is a partnership between University of Glamorgan, Cardiff University, Amgueddfa Cymru-National Museum Wales, Techniquest and BBC Cymru Wales and helps to support, recognise, reward and build capacity for public engagement work. The purpose of yesterday’s event was to highlight some examples of projects funded by the organisation and to showcase the Beacon for Wales.

Dr Rachel Iredale was invited to give a presentation on the GAMY project, which involved engaging with a group of young people aged 16 to 19 to explore their attitudes towards genetics, how these attitudes were formed and whether they changed over time. Fellow GAMY team members Kim Madden and Nicki Taverner also attended the event and fielded lots of questions about the project from interested parties. The Glamorgan stand was also manned by GPU members Juping Yu and Rhian Morgan. Juping received funding from Beacon for Wales for a recent project which involved engaging young people in an online focus group , and Rhian attended in her capacity as project officer for the Glamorgan-based Telling Stories, Understanding Real Life Genetics project and as a representative of the NHS National Genetics Education and Development Centre and to promote the involvement of the GPU’s work in genetics education.

The event was attended by members of the public, representatives from various Beacon’s projects and Welsh universities and by several Assembly members. The GPU and GAMY girls wasted no time in seizing the chance to lobby some of the AMs about possible funding opportunities and even got in on some photo opportunities.

Left to right: Rachel Iredale, Kim Madden, Nicki Taverner, Juping Yu and Rhian Morgan

Posted by Rhian Morgan | 0 comments

The BBC website reports that scientists have developed a gene test which predicts how well chemotherapy will work in cancer patients.

Starting with 829 genes in breast cancer cells, the team whittled down the possibilities to six genes which had an impact on whether a drug worked. They then showed that these genes could be used to predict the effectiveness of a drug called paclitaxel in patients. It is hoped the approach, reported in The Lancet Oncology, can be replicated for other cancers and treatments.

More than 45,500 women are diagnosed with breast cancer in the UK each year – and it is estimated that around 15% of these women will be prescribed paclitaxel. The researchers estimate they could potentially spare half of the patients currently receiving this drug from treatment which would not be effective.

Posted by Rhian Morgan | 0 comments | Tagged with , ,

When the competence-based genetics education framework for nurses and midwives (Fit for Practice in the Genetics Era) was launched in 2004, we said then that it should be reviewed in 5 years or so. Last Thursday (February 25th) at Birmingham, we met with 30 stakeholders (including patients and carers, nurse educators, practitioners, representatives from the NMC and RCN, and genetic counsellors) from across the UK to do just that.

Staff from the Centre (including Maggie and Emma) joined with colleagues Marcus Longley, Kevin McDonald and Heather Skirton in planning for what was a positive and successful day. Another colleague from the Faculty of Health, Sport and Science, Ian Mansell, joined us to represent the RCN Learning Disability Forum. Jimby also came to lend support once again, and I was pleased to see him wearing his Wales badge!

We used real life stories (from Telling Stories)to form the basis of group discussions that considered the patient/family needs and the knowledge and skills needed by nurses to meet those needs. Through an iterative process, each group was able to comment on the issues identified by the other groups. In a plenary afternoon session, we then fed back on the group discussions, and used electronic voting to capture views.

It was a very busy and lively meeting and I was impressed with the level of commitment that people showed in engaging with the ‘business’ of the day – we had to shoo people away from the group work so that they could go and enjoy the lunch available!

Over the next few months, we will be refreshing the framework, based on the discussions held. What I hope will result is a framework that is fit for the genetics and genomics era.

Posted by Maggie Kirk | 0 comments | Tagged with ,

February 28th is Rare Disease Day and to mark the event, the Welsh Assembly is hosting a reception this evening at the Senedd.

So far, between 6000 – 8000 rare diseases have been identified, affecting around 1 in 17 people in the UK. So whilst individual diseases may affect less than 5 in 10,000 people, collectively, they are not rare at all. Around 80% are genetic in origin, and there is no cure for the great majority. One of the purposes of Rare Disease Day is to provide ‘one voice’ for this sizeable patient group.

Dr Rhian Morgan, Project Officer for Telling Stories, is attending on behalf of the GPU and NHS National Genetics Education & Development Centre in Wales. Many of the stories on our website are from people or families affected by a rare condition and there is often a common thread through their stories as they ask for their voices to be heard.

A European survey in 2003 of patient groups highlighted the importance of being given information about the rare condition. Lack of information and the absence of a diagnosis were key obstacles to practical support, leading to a sense of isolation. Families often have to struggle to get the support and information they need.

As advances in research shift the focus of genomic healthcare onto the common complex conditions in which genetics plays a significant part, it is important to remember that those affected by rare diseases continue to need care and support from health professionals who, whilst not necessarily knowing about the individual condition themselves, do know where to go to get information.

Posted by Maggie Kirk | 0 comments | Tagged with

Netdoctor News

Scottish scientists have discovered a link between deprivation and a gene involved in breast cancer.

The finding, which is published in the British Journal of Cancer, may help to explain why women from deprived backgrounds are less likely to survive breast cancer.

Researchers at the University of Dundee found that women from poorer backgrounds were more likely to have a faulty p53 gene, increasing their chances of relapse and death from the disease.

Dr Lee Baker, from the university’s department of surgery and molecular oncology, revealed that p53 mutations can come about in two ways – as a result of genetic predisposition and because of a poor lifestyle.

‘Smoking, drinking, poor diet etc can lead to p53 mutations and are more common in women from lower socio-economic groups, who are also more likely to experience a recurrence of the disease and to die as a result of breast cancer,’ he revealed.

‘This research makes a strong link between p53 and deprivation, and then between p53 mutation and recurrence and death.’

The scientist claimed that by lifting people out of deprivation, it may be possible to reduce their chances of having problems with their p53 gene and to ultimately reduce their risk of developing breast cancer.

Dr Caitlin Palframan, policy manager at Breakthrough Breast Cancer, commented that the reasons for the connection between deprivation and breast cancer survival are not yet known.

However, she noted that ‘a range of lifestyle, environmental and genetic factors are all likely to play a part’.

Posted by Juping Yu | 0 comments | Tagged with ,

UK scientists have identified genetic ‘hotspots’ that could help doctors to tailor bowel cancer treatment to suit individual patients.

A team at the University of Dundee calculated that one in three people with the disease have gene faults that mean common drugs will not work for them.

The researchers analysed samples from 106 bowel cancer patients to see how often known faults in the K-Ras gene occurred.

The gene encodes a protein that is required to switch cell growth on and off, and is known to be faulty in some bowel cancers, causing the switch to be permanently ‘on’ and allowing uncontrolled cell growth.

Writing in the British Journal of Cancer, the study authors revealed that faults in this gene are even more common than previously thought, meaning that around 12,375 out of the 37,500 people diagnosed with bowel cancer each year in the UK probably have a K-Ras fault.

Professor Roland Wolf, who co-authored the study, explained: ‘These findings may in the future be relevant for selected patients with advanced bowel cancer as doctors will be able to more precisely target these treatments to the patients who will benefit and avoid treating those who won’t.’

Bowel cancer is the third most common cancer in the UK, with the majority of cases diagnosed in people over the age of 60.

Posted on behalf of Prof Maggie Kirk

Posted by Rhian Morgan | 0 comments | Tagged with , , , , ,

The European Society of Human Genetics offers fellowships for next Spring Courses. If you wish to apply for a fellowship, please send your request together with your CV and a reference letter to the following e-mail address: esgm.fellowships@eshg.org

Please quote in the subject the title of the course you wish to attend (see below). ESHG Fellowships cover registration fee (tuition, course material, lunch, coffee break and shuttle bus from the meeting point to the venue and back).

CALENDAR OF SPRING COURSES

1. Course in Genetics and Molecular Pathology of Age Related Neurodegenerative Diseases March 29-31, 2010 – EuroMediterranean University Centre of Ronzano, Bologna (Italy)

2. Course in Mitochondrial Metabolism and Cancer April 20-23, 2010 – EuroMediterranean University Centre of Ronzano, Bologna (Italy)

3. Course in Genomic and Cultural Evolution of Humans May 17-19, 2010 – EuroMediterranean University Centre of Ronzano, Bologna (Italy)

4. 23rd Course in Medical Genetics May 23-28, 2010 – EuroMediterranean University Centre of Ronzano, Bologna (Italy)

5. 6th Course in Statistical Genetic Analysis of Complex Phenotypes June 21-24, 2010 – EuroMediterranean University Centre of Ronzano, Bologna (Italy)

For further info on these residential ESGM 2010 courses please click on the titles above, or visit www.eurogene.org or contact courses@eurogene.org

EXPRESSIONS OF INTEREST FOR LIVE WEBCASTING

They are collecting the expressions of interest of Remote Training Centres which intend to follow via internet the Live version of ESGM courses (in the Hybrid courses format).

Should your Institution be interested in joining our network of Remote Training Centres, please contact giuseppe.curcio@eurogene.org.

Posted by Juping Yu | 0 comments | Tagged with ,

Yu J (2009) Young people of Chinese origin in western countries: a systematic review of their sexual attitudes and behaviour. Health & Social Care in the Community, 18(2):117-128.

Juping is very pleased that one of her papers has just been published in the journal Health and Social Care in the Community. The paper reports on a systematic review of sexual attitudes and behaviour among ethnic Chinese young people living in western countries.

This is GPU’s second publication this week, following Verity’s paper published earlier this week. A good start of GPU’s another productive year, isn’t it?

Posted by Juping Yu | 0 comments | Tagged with , , ,

Verity Leach is a PhD student at the Genomics Policy Unit. Her first paper entitled “Gender Differences in Attitudes towards Genetic Testing, Risk Interpretation and Genetic Testing Concerns” has just been published in the Journal of Young Investigators. The paper is based on the project carried out for her BSc study at the University of Swansea. The full text of the paper can be found here

Many congratulations. Well done Verity.

Posted by Juping Yu | 6 comments | Tagged with , ,

Netdoctor Stories

The discovery of two genes that enable cancer cells to resist some chemotherapy drugs may lead to a new test to help doctors decide the best treatment for individual patients.

Researchers at the Dana-Farber Cancer Institute in Boston analysed the DNA in samples of tissue taken from breast cancer patients. They identified two genes that, when faulty, enable tumour cells to resist a common class of chemotherapy drug called anthracyclines. However, further research revealed that despite their resistance to these drugs, cells with overactive versions of the genes are still vulnerable to other drugs such as cisplatin and paclitaxel.

Lead researcher Dr Andrea Richardson, whose findings are published in the journal Nature Medicine, commented: ‘These results suggest that tumours resistant to anthracyclines may still be sensitive to other agents.

‘So this would be very useful as a test to help pick the therapy that’s going to be most effective for these patients.’

Meg McArthur, a spokeswoman for Breakthrough Breast Cancer, said that the research is ‘important’ for identifying appropriate treatments for individual patients. She noted: ‘These are early, small-scale study results and more research is now needed before the benefits could be seen by patients.’

Posted by Juping Yu | 0 comments | Tagged with ,

2010 brings in changes and updates to our Telling Stories, Understanding Real Life Genetics website. From today (Monday 18th January 2010) our new web address will be www.tellingstories.nhs.uk

The Telling Stories website continues to be hosted by the NHS National Genetics Education and Development Centre and if you have already bookmarked our website, the original web address will still work (redirecting you to our new homepage).

To find out more about all the latest Telling Stories news and new features including our new stories, new ‘Frequently Asked Questions’ guide, new expert commentaries and new online questionnaire, visit our website and read our latest bulletin and please remember to add Telling Stories to your favourites for 2010!

Posted by Rhian Morgan | Tagged with , , ,

Cashing in on your genes

January 11th, 2010

A recent article in The Times reports on the growing business of personal DNA testing and the safety of our genetic data. Click here to read more.

Posted by Rhian Morgan | 0 comments

BBC News today says that after all the concern over possible damage to health from using mobile phones, scientists have found a potential benefit from radiation.

Their work has been carried out on mice, but it suggests mobiles might protect against Alzheimer’s. Florida scientists found that phone radiation actually protected the memories of mice programmed to get Alzheimer’s disease. They are now testing more frequencies to see if they can get better results.

The study by the Florida Alzheimer’s Disease Research Centre is published in the Journal of Alzheimer’s Disease.

The full story can be found here.

Posted by Juping Yu | 1 comment | Tagged with , , ,

Is embryo screening test safe?

December 22nd, 2009

BBC News reports that an embryo screening test called pre-implantation genetic diagnosis (PGD) is safe for the children of singleton pregnancies, Belgian researchers say.

They looked at 581 children born at one Belgian centre over 13 years who had been screened using the PGD technique. They found that rates of birth defects and deaths were similar to those of children born using other IVF methods. However, significantly more deaths just after or before the birth were seen in multiple pregnancies following PGD.

The findings come after concerns that the PGD screening technique, which involves removing some of the embryo’s cells at an early stage, could lead to problems. But the researchers, writing in the journal Human Reproduction, found no significant difference in birth defect rates when compared to 2,889 children born using IVF but who did not undergo the screening.

More perinatal deaths

In total, 2.13% of PGD children had birth defects compared with 3.38% of the other children. The perinatal death rate – the period immediately before and after birth – was also similar at just over 1% for singleton children in both groups. However, for multiple pregnancies there was a difference. In the PGD group it was 11.73%, whereas among the others it was 2.54%.

Professor Inge Liebaers, head of the centre for medical genetics at the University Hospital Brussels, said:”At present, we don’t have an explanation for why the perinatal death rate (for multiple pregnancies) should be so much higher in the PGD children, and we need to be careful about drawing firm conclusions from these observations as they may be biased due to low numbers.

“There is a need for more careful, thorough and long-term follow-up studies after PGD and the number of cases needs to be expanded.

“The parents-to-be need to be fully informed on the health of offspring.

“Unfortunately, funding for these studies is hard to find.”

In an accompanying editorial, Professor Joe Leigh Simpson, of the Florida International University, said that Professor Liebaers’ study was as good as it gets and showed that: “in experienced hands, removal of one (or more) blastomeres does not result in an increase in birth defects.

“Whatever the controversy concerning efficacy of PGD in increasing pregnancy rates, patients may be informed that PGD is safe.”

Posted by Juping Yu | 0 comments | Tagged with , ,

Gene that keeps women 'female'

December 11th, 2009

Scientists have located the gene that keeps women ‘female’ and could pave the way for the creation of drugs that will delay the menopause. Scientists reported in the journal Cell that only one gene, FoxL2 prevents adult ovary cells from turning into cells found in testes. The FoxL2 gene however, is on an autosomal chromosome, so both males and females have the gene.

FoxL2 represses a DNA element called TESCO, that in turn regulates the expression of the gene Sox9; the testes promoting gene that makes early gonads become testes rather than ovaries. It is now believed that these genes can also perform the same task in adults, therefore FoxL2 is important in keeping Sox9 turned off in ovaries throughout life.

The finding is helping to understand the condition of early menopause and could one day lead to the creation of a drug that could delay the menopause and preserve a woman’s ‘stock of eggs’. It also highlights the fact that sex is not solely determined by X and Y chromosomes. Therefore it could also remove the need for surgery in sex-change operations as this finding creates an ability to turn ovaries into testes.

The full article can be found here

Posted by Verity Leach | 0 comments


Tags

Atom Feeds

Entries
Comments

RSS Feeds

Entries
Comments

University of Glamorgan

Pontypridd, CF37 1DL, UK.

© University of Glamorgan